default author photo

Mushira Enani

King Fahad Medical City - Infectious Diseases Section

Riyadh

Saudi Arabia

  • King Fahad Medical City - Infectious Diseases Section

SCHOLARLY PAPERS

2

DOWNLOADS

123

TOTAL CITATIONS

2

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

Silent Transmission of SARS-CoV-2 Among Ambulatory Influenza Like Illness (ILI) Patients

Number of pages: 26 Posted: 10 Oct 2020
Bandar Alosaimi, Asif Naeem, Majed Alghoribi, Lilian Okdah, Maaweya E. Hamed, Ahmad S. AlYami, Athari Alotaibi and Mushira Enani
King Fahad Medical City - Research Center, King Fahad Medical City - Research Center, King Abdullah International Medical Research Center, King Abdullah International Medical Research Center, King Saud University - College of Science, King Fahad Medical City - Pathology and Clinical Laboratory Medicine Administration, Ministry of Health, Saudi Arabia - General Administration for Research and Studies and King Fahad Medical City - Infectious Diseases Section
Downloads 84 (777,583)

Abstract:

Loading...

Silent transmission, SARS-CoV-2, next generation sequencing, NGS, Influenza Like Illness, COVID-19, influenza, vaccine, coronavirus.

2.

Combination of (Interferon beta-1b, Lopinavir-Ritonavir and Ribavirin) versus Favipiravir in Hospitalized Patients with Non-Critical COVID-19: A Cohort Study

Number of pages: 34 Posted: 17 Mar 2021
Areej A. Malhani, Mushira Enani, Fatemeh Saheb Sharif-Askari, Mona R. Alghareeb, Roaa T. Bin-Brikan, Safar A. AlShahrani, Rabih Halwani and Imad M. Tleyjeh
King Fahad Medical City - Clinical Pharmacy Department, King Fahad Medical City - Infectious Diseases Section, University of Sharjah - Sharjah Institute of Medical Research, King Fahad Medical City - Clinical Research Coordinator, King Fahad Medical City - Clinical Research Coordinator, King Fahad Medical City - Outpatient Pharmacy Department, University of Sharjah - Sharjah Institute of Medical Research and King Fahad Medical City - Infectious Diseases Section
Downloads 39 (1,196,171)
Citation 2

Abstract:

Loading...

Interferon-B 1b, Triple therapy, Lopinavir-ritonavir, Ribavirin, Favipiravir, COVID-19, 28-days mortality